Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997649 | 0.97 | HTR1B (0.44) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL15441814 | 0.97 | EPHX1 (0.48) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL25962544 | 0.94 | EPHX1 (0.52) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL837471 | 0.94 | EPHX1 (0.52) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL11546652 | 0.94 | EPHX1 (0.52) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL13312991 | 0.94 | EPHX1 (0.52) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL8352992 | 0.94 | HTR1B (0.46) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL18902629 | 0.92 | EPHX1 (0.43) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL13997648 | 0.91 | HTR1B (0.44) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 | |
| SCHEMBL7221701 | 0.91 | HTR1B (0.44) | EPHX1HTR1BL3MBTL1SLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-9347054-B2 | Polymer factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | NEKTAR THERAPEUTICS | 2015-02-05 | — | — | US | disclosed |
| US-8889831-B2 | Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate | NEKTAR THERAPEUTICS (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140141483-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | NEKTAR THERAPEUTICS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | F8, F13B, F13A1 | EPHX1 1467/4885HTR1B 3403/4885L3MBTL1 3884/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | EPHX1 459/4885HTR1B 4803/4885L3MBTL1 3230/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | EPHX1 493/4885HTR1B 4813/4885L3MBTL1 3235/4885 |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | EPHX1 2991/4885HTR1B 4780/4885L3MBTL1 2700/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | EPHX1 966/4885HTR1B 4239/4885L3MBTL1 2678/4885 |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | EPHX1 459/4885HTR1B 4803/4885L3MBTL1 3230/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | EPHX1 2439/4885HTR1B 4768/4885L3MBTL1 755/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | EPHX1 2395/4885HTR1B 3668/4885L3MBTL1 1521/4885 |
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | CSF3R, GMFG, CSF1R | EPHX1 1849/4885HTR1B 4767/4885L3MBTL1 1272/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | EPHX1 459/4885HTR1B 4803/4885L3MBTL1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.